drugset
Drugs / QVA149
last change Oct 2022 re-read 2 minutes ago

QVA149

also known as Indacaterol glycopyrronium · QVA149A

Other / unclassified

Developed for
chronic obstructive pulmonary disease
Investigated by
Novartis Pharmaceuticals · Università degli Studi di Ferrara

Trials 13 · a red edge is where a trial was stopped

today NCT03662711 · Ph 4 NCT02634983 · Ph 4 NCT02603393 · Ph 4 NCT02487446 · Ph 3 NCT02125734 · Ph 4 NCT01834885 · Ph 3 NCT01860066 · Ph 3 NCT01712516 · Ph 3 NCT01682863 · Ph 3 NCT01610037 · Ph 3 NCT01529632 · Ph 3 NCT01574651 · Ph 3 NCT01490125 · Ph 3
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 39 trials
Phase 3 NCT02487446 Jul 2015 → Sep 2016 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT01834885 Dec 2013 → Sep 2014 chronic obstructive pulmonary disease Novartis Pharmaceuticals Withdrawn No outcome recorded
Phase 3 NCT01860066 Dec 2013 → Sep 2014 chronic obstructive pulmonary disease Novartis Pharmaceuticals Withdrawn No outcome recorded
Phase 3 NCT01712516 Dec 2012 → Feb 2014 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT01682863 Oct 2012 → Jun 2014 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT01610037 Oct 2012 → Feb 2015 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT01529632 May → Dec 2012 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT01574651 May 2012 → Apr 2013 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 3 NCT01490125 Oct 2011 → Aug 2012 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 44 trials
Phase 4 NCT03662711 Nov 2018 → Oct 2022 chronic obstructive pulmonary disease Università degli Studi di Ferrara Terminated No outcome recorded
Phase 4 NCT02634983 Jun 2016 → Sep 2017 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 4 NCT02603393 Nov 2015 → Jul 2017 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded
Phase 4 NCT02125734 Apr 2014 → Jan 2015 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2015-05-20 Novartis Pharmaceuticals Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 novartis.com ↗
2015-01-08 Novartis Pharmaceuticals Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA novartis.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as QVA149 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02487446 ↗
11

NCT02125734 ↗

NCT01529632 ↗

NCT02603393 ↗

NCT01682863 ↗

NCT01712516 ↗

NCT01860066 ↗

NCT01490125 ↗

NCT01834885 ↗

NCT02634983 ↗

NCT01610037 ↗

NCT01574651 ↗
Known as Indacaterol glycopyrronium “Indacaterol glycopyrronium” NCT03662711 ↗
Known as QVA149A “Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate...” NCT01610037 ↗
Modality Other / unclassified “The long-acting β2-agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY)” PMID 35144620 ↗ Feb 2022
Route Inhaled “QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI” NCT01490125 ↗